GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q2 FY25 results · Jul–Sep 2024
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹1,010.77 crore (up 5.6% from Q2 FY24) and net profit of ₹252.50 crore (up 16.1% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,010.77 | 956.99 | +5.6% | 814.65 | +24.1% |
| Other income | 34.54 | 28.21 | +22.4% | 35.64 | −3.1% |
| Total income | 1,045.31 | 985.20 | +6.1% | 850.29 | +22.9% |
| Profit before tax | 343.81 | 299.16 | +14.9% | 249.40 | +37.9% |
| Net profit for the period | 252.50 | 217.51 | +16.1% | 182.33 | +38.5% |
| EPS, basic (₹) | 14.67 | 12.84 | +14.3% | 10.76 | +36.3% |
| Net margin (%) | 25.0 | 22.7 | 22.4 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,000.05 | 953.38 | +4.9% | 811.00 | +23.3% |
| Other income | 32.19 | 28.47 | +13.1% | 35.85 | −10.2% |
| Total income | 1,032.24 | 981.85 | +5.1% | 846.85 | +21.9% |
| Profit before tax | 338.70 | 296.51 | +14.2% | 248.49 | +36.3% |
| Net profit for the period | 248.69 | 215.54 | +15.4% | 181.65 | +36.9% |
| EPS, basic (₹) | 14.45 | 12.72 | +13.6% | 10.72 | +34.8% |
| Net margin (%) | 24.9 | 22.6 | 22.4 |
Consolidated
- Filed with BSE
- 30 Oct 2024, 13:15 IST
- Board meeting
- 29 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Oct 2024, 13:15 IST
- Board meeting
- 29 Oct 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE